Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives.

Bioorganic & medicinal chemistry letters - 1 Aug 2013

Belema Makonen, Nguyen Van N, St Laurent Denis R, Lopez Omar D, Qiu Yuping, Good Andrew C, Nower Peter T, Valera Lourdes, O'Boyle Donald R, Sun Jin-Hua, Liu Mengping, Fridell Robert A, Lemm Julie A, Gao Min, Knipe Jay O, Meanwell Nicholas A, Snyder Lawrence B

Abstract excerpt

The isoquinolinamide series of HCV NS5A inhibitors exemplified by compounds 2b and 2c provided the first dual genotype-1a/1b (GT-1a/1b) inhibitor class that demonstrated a significant improvement in potency toward GT-1a replicons compared to that of the initial program lead, stilbene 2a. Structur...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crystallography, X-Ray
Share to Drug Evaluation, Preclinical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycine

Share to Half-Life

Share to Microsomes, Liver

Share to Molecular Conformation

Share to Viral Nonstructural Proteins

Share to Virus Replication

Source

Identifiers

PMID: 23803586
DOI: 10.1016/j.bmcl.2013.05.040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23803586-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives.PMID 23803586Read ↗

HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.Semantic proximity Read ↗

Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.Semantic proximity Read ↗

Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors.Semantic proximity Read ↗

Identification and biological evaluation of a series of 1H-benzo[de]isoquinoline-1,3(2H)-diones as hepatitis C virus NS5B polymerase inhibitors.Semantic proximity Read ↗

GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.Semantic proximity Read ↗

Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency.Semantic proximity Read ↗

Highly potent HCV NS4B inhibitors with activity against multiple genotypes.Semantic proximity Read ↗

Expanding the chemical space of anti-HCV NS5A inhibitors by stereochemical exchange and peptidomimetic approaches.Semantic proximity Read ↗

Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect.Semantic proximity Read ↗

Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.Semantic proximity Read ↗

Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor.Semantic proximity Read ↗

Discovery and Development of Hepatitis C Virus NS5A Replication Complex InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.